Paracentesis is the standard treatment for refractory ascites in patients with cirrhosis, but it cannot prevent the recurrence of ascites. The placement of a transjugular intrahepatic portosystemic ...

BD (Becton, Dickinson and Company) announced European CE Mark approval for the Liverty transjugular intrahepatic portosystemic sh ...

A new prognostic score is more accurate than the commonly used Model for End-Stage Liver Disease (MELD) in predicting post–transjugular intrahepatic portosystemic shunt (TIPS) survival, researchers ...

In patients with cirrhosis and acute fundal variceal bleeding, the use of preemptive transjugular intrahepatic portosystemic shunt (p-TIPS) with a covered stent within 72 hours of initial bleeding ...

Designed to expand treatment options for patients with cirrhosis and complications of portal hypertension, this ...

Becton, Dickinson and Company BDX, popularly known as BD, recently announced that it has applied for CE Mark approval for its ...

Liver regeneration after radiotherapy in patients with hepatocellular carcinoma: A simple-to-use model and nomogram. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract ...

The progressive worsening of liver cirrhosis and portal hypertension (HTN) decreases intra-hepatic nitric oxide (NO), which is counterbalanced by increased NO secretion from adjacent endothelial cells ...

BD delivers next-generation TIPS innovation to advance portal hypertension care across the European Union: Franklin Lakes, ...

Acquired SEPS are associated with portal hypertension, cirrhosis, and complications of decompensation. In particular, the effects of NVEPS on portal pressure are variable, but there is evidence of ...